Table 1.
Parameters | Number of cases (%) |
---|---|
Sex | |
Male | 97 (99.0%) |
Female | 1 (1.0%) |
Age (years) (Median, 68; range, 34–87) | |
≤40 | 20 (20.4%) |
41–50 | 35 (35.7%) |
51–60 | 30 (30.6%) |
61–70 | 10 (10.2%) |
71–80 | 3 (3.1%) |
81–90 | 1 (1.0%) |
Tumor location | |
Tongue | 40 (40.8%) |
Buccal | 37 (37.8%) |
Others | Lip (6), mouth floor (6), palate (5), trigone (4) |
Primary tumor (T) | |
T1 | 18 (18.4%) |
T2 | 31 (31.6%) |
T3 | 17 (17.3%) |
T4 | 32 (32.7%) |
Nodal status (N) | |
N0 | 38 (46.3%) |
N1 | 14 (17.1%) |
N2 | 30 (36.6%) |
Nx | 16 |
Extracapsular extension of metastatic nodes | |
Present | 32 (61.5%) |
Absent | 20 (38.5%) |
Histological grade | |
Well differentiated | 61 (62.2%) |
Moderately differentiated | 29 (28.6%) |
Poorly differentiated | 9 (9.2%) |
Vascular invasion | |
Present | 18 (18.4%) |
Absent | 80 (81.6%) |
Perineurial invasion | |
Present | 26 (26.5%) |
Absent | 72 (73.5%) |
Tumor necrosis | |
Present | 38 (38.8%) |
Absent | 60 (61.2%) |
CIS at adjacent mucosa | |
Present | 24 (24.5%) |
Absent | 74 (75.5%) |
Surgical margin | |
Clear (≥5 mm) | 91 (94.8%) |
Unclear | 5 (5.2%) |
Not assessable | 2 |
RSF-1 expression | |
Low expression (0+∼2+) | 44 (44.9%) |
Overexpression (3+∼4+) | 54 (55.1%) |
CIS, carcinoma in situ.